The Long Island Parkinson's Disease Center

长岛帕金森病中心

• 批准号: 6660404
• 负责人: ANDREW FEIGIN
• 金额: $ 11.99万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6660404
• 关键词: Parkinson's disease; biomarker; chemoprevention; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder therapy; neuroimaging; neuropharmacology; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. With advances in the understanding of the pathophysiology PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have assembled a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. With this combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to achieve the following Specific Aims: 1) To participate successfully in the planned large-scale simple neuroprotective clinical trial for PD. At North Shore University Hospital (NSUH) we have a long track record of successful completion of clinical trials for PD and of recruitment for clinical research; and 2) To provide expertise regarding potential neuroimaging markers for the planned clinical trial. The functional imaging laboratory at NSUH has focused on the assessment of therapies for PD. Drs. Feigin and Eidelberg are currently funded by NINDS to study issues directly related to the assessment of potential neuroprotective agents for PD and therefore have a unique perspective that may be of benefit for the planning of the future clinical trial. To support our contention that we can successfully achieve these Specific Aims, this application will focus on five areas: 1) The demographics of our catchment area; 2) A description of our current PD patient population and our multidisciplinary PD center; 3) Plans to further enhance recruitment for the planned clinical trial; 4) The experience of our center personnel with all aspects of clinical trial conduct both through multicenter consortiums and independently; and 5) A brief description of our imaging studies of therapies for PD.

描述（由申请人提供）：帕金森病 (PD) 是一种常见的退行性神经系统疾病，影响大约 100 万美国人。过去十年来，帕金森病治疗和管理的进步越来越需要普通神经科医生向运动障碍专家寻求建议，以优化帕金森病患者的护理。随着对帕金森病病理生理学认识的进步，减缓帕金森病进程的新策略正在出现。随着这些疗法已开始进入临床试验，患者参与这些试验的途径已经并将可能继续主要通过 PD 中心进行。我们在纽约长岛或其附近组建了一个由帕金森病专家组成的网络，他们拥有帕金森病管理方面的实践经验、丰富的临床试验经验以及与开发用于评估帕金森病疗法的成像方法相关的卓越临床研究。凭借帕金森病临床试验和研究经验以及非常广泛的人群基础，我们具有独特的优势来实现以下具体目标：1）成功参与计划中的帕金森病大规模简单神经保护临床试验。在北岸大学医院 (NSUH)，我们拥有成功完成 PD 临床试验和临床研究招募的长期记录； 2) 为计划的临床试验提供有关潜在神经影像标记物的专业知识。 NSUH 的功能成像实验室专注于帕金森病治疗的评估。博士。 Feigin 和 Eidelberg 目前由 NINDS 资助，研究与评估帕金森病潜在神经保护药物直接相关的问题，因此拥有独特的视角，可能有利于未来临床试验的规划。为了支持我们能够成功实现这些具体目标的论点，该应用程序将重点关注五个领域： 1) 我们服务区域的人口统计； 2) 对我们当前 PD 患者群体和我们的多学科 PD 中心的描述； 3）计划进一步加强拟定临床试验的招募； 4) 我们中心人员通过多中心联合体和独立进行临床试验各方面的经验； 5) 简要描述我们的 PD 治疗影像学研究。